Evidence map›Paper›PMID 26925801›Full record

ArticleSchizophrenia research2016

Prefrontal neuronal integrity predicts symptoms and cognition in schizophrenia and is sensitive to genetic heterogeneity.

Dolores Malaspina, Thorsten M Kranz, Adriana Heguy, Sheila Harroch, Robert Mazgaj, Karen Rothman, Adam Berns, Sumya Hasan, Daniel Antonius, Raymond Goetz and 3 more

Abstract read
In one paragraph

Article in Schizophrenia research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Dolores MalaspinaInstitute for Social and Psychiatric Initiatives (InSPIRES), Department of Psychiatry, New York University School of Medicine, NY, NY, USA. Electronic address: dolores.malaspina@nyumc.org.
Thorsten M KranzSkirball Institute of Biomolecular Medicine, Departments of Cell Biology, Physiology & Neuroscience and Psychiatry, New York University, New York, NY 10016, USA.
Adriana HeguyGenome Technology Center, New York University School of Medicine, NY, NY, USA.
Sheila HarrochDepartment of Psychiatry, New York University School of Medicine, NY, NY, USA.
Robert MazgajInstitute for Social and Psychiatric Initiatives (InSPIRES), Department of Psychiatry, New York University School of Medicine, NY, NY, USA.
Karen RothmanInstitute for Social and Psychiatric Initiatives (InSPIRES), Department of Psychiatry, New York University School of Medicine, NY, NY, USA.
Adam BernsInstitute for Social and Psychiatric Initiatives (InSPIRES), Department of Psychiatry, New York University School of Medicine, NY, NY, USA.
Sumya HasanInstitute for Social and Psychiatric Initiatives (InSPIRES), Department of Psychiatry, New York University School of Medicine, NY, NY, USA.
Daniel AntoniusUniversity at Buffalo, Department of Psychiatry, Buffalo, NY, USA.
Raymond GoetzNew York State Psychiatric Institute, Division of Clinical Phenomenology, 1051 Riverside Drive, NY, NY, USA; Columbia University, Department of Psychiatry, NY, NY, USA.
Mariana LazarCenter for Advanced Imaging Innovation and Research (CAI2R), Department of Radiology, New York University School of Medicine, NY, NY, USA; Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, NY, NY, USA.
Moses V ChaoSkirball Institute of Biomolecular Medicine, Departments of Cell Biology, Physiology & Neuroscience and Psychiatry, New York University, New York, NY 10016, USA.
Oded GonenCenter for Advanced Imaging Innovation and Research (CAI2R), Department of Radiology, New York University School of Medicine, NY, NY, USA; Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, NY, NY, USA.
New York University · USAdvanced Imaging Research (United States) · USColumbia University · USInspire Institute · USNew York Genome Center · USUniversity at Buffalo, State University of New York · US

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
TR&D 4: Revealing Microstructure: Biophysical modeling and validation for discovery and clinical careP41EB017183 · NIBIB · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Hersh Chandarana · 2014 to 2026
$19.3M
Institutional Clinical and Translational Science AwardUL1TR000038 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL, HOCHMAN, JUDITH S · 2012 to 2014
$16.8M
Jerusalem Perinatal Cohort Schizophrenia Study IIR01MH059114 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MALASPINA, DOLORES · 1999 to 2011
$7.3M
HIGHER SPEED, FIELD &SPATIAL RESOLUTION BRAIN 3D 1H MRSR01EB001015 · NIBIB · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GONEN, ODED · 2002 to 2011
$5.8M
Mechanisms of BDNF and Glucocorticoid ActionR01MH086651 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHAO, MOSES VICTOR, GARABEDIAN, MICHAEL J. · 2009 to 2013
$3.1M
Mentoring Translational Schizophrenia ResearchersK24MH001699 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MALASPINA, DOLORES · 2000 to 2009
$1.3M
Paternal Age Related Schizophrenia as a Discrete DisorderRC1MH088843 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MALASPINA, DOLORES · 2009 to 2010
$979k
Molecular Analysis of Neurotrophin ActionR56NS021072 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHAO, MOSES VICTOR · 2011 to 2017
$882k
NCATS NIH HHS UL1 TR000038NCATS NIH HHS UL1TR000038NCATS NIH HHS UL1 TR001445NIBIB NIH HHS EB01015NIBIB NIH HHS P41 EB017183NIBIB NIH HHS R01 EB001015NIMH NIH HHS 5K24MH001699NIMH NIH HHS K24 MH001699NIMH NIH HHS MH086651NIMH NIH HHS R01 MH059114NIMH NIH HHS R01 MH086651NIMH NIH HHS R01-MH59114NIMH NIH HHS RC1 MH088843NIMH NIH HHS RC1-MH088843NINDS NIH HHS R56 NS021072
6 · The paper itself

Abstract

Schizophrenia is a genetically complex syndrome with substantial inter-subject variability in multiple domains. Person-specific measures to resolve its heterogeneity could focus on the variability in prefrontal integrity, which this study indexed as relative rostralization within the anterior cingulate cortex (ACC). Twenty-two schizophrenia cases and 11 controls underwent rigorous diagnostic procedures, symptom assessments (PANSS, Deficit Syndrome Scale) and intelligence testing. All underwent multivoxel MRSI at 3T to measure concentrations of the neuronal-specific biomarker N-acetylaspartate (NAA) in all of the voxels of the ACC. The concentrations of NAA were separately calculated and then compared across the rostral and caudal subregions to generate a rostralization ratio, which was examined with respect to the study measures and to which cases carried a missense coding polymorphism in PTPRG, SCL39A13, TGM5, NTRK1 or ARMS/KIDINS220. Rostralization significantly differed between cases and controls (χ(2)=18.40, p<.0001). In cases, it predicted verbal intelligence (r=.469, p=.043) and trait negative symptoms (diminished emotional range (r=-.624, p=.010); curbed interests, r=-.558, p=.025). Rostralization was similar to controls for missense coding variants in TGM5 and was significantly greater than controls for the PTPRG variant carrier. This is the first study examining the utility of MRS metrics in describing pathological features at both group and person-specific levels. Rostralization predicted core illness features and differed based on which signaling genes were disrupted. While future studies in larger populations are needed, ACC rostralization appears to be a promising measure to reduce the heterogeneity of schizophrenia for genetic research and selecting cases for treatment studies.

Indexed as

Schizophrenic PsychologyAdultAspartic AcidCognitionFemaleHumansIntelligence TestsMagnetic Resonance ImagingMaleMembrane ProteinsMutation, MissenseNerve Tissue ProteinsPolymorphism, GeneticPrefrontal CortexPsychiatric Status Rating ScalesPsychotic DisordersAspartic AcidKIDINS220 protein, humanMembrane ProteinsN-acetylaspartateNerve Tissue ProteinsPTPRG protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 5Anterior cingulate cortexGenotypeMagnetic resonance spectroscopy imagingN-acetylaspartateRostralizationSchizophrenia

Identifiers

PMID26925801
PMCPMC4894496
OpenAlexW2284077475

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.